DUBLIN, July 29, 2019 /PRNewswire/ -- Allergan plc (NYSE:
AGN) announced today a partnership with actress, musician and
producer Ashley Tisdale, bringing
awareness to the digital-first 'Women Who Know' campaign that
inspires women who are writing their own futures to take charge of
their decisions when it comes to reproductive health and
contraceptive options.
Allergan, the maker of the #1-prescribed branded birth control
pill by OB/GYNs,1 Lo
Loestrin®Fe (norethindrone acetate and ethinyl
estradiol tablets, ethinyl estradiol tablets and ferrous fumarate
tablets), has chosen Tisdale to represent the 'Woman Who Knows,' a
confident, savvy and empowered woman looking to be proactive about
her individual journey with pregnancy prevention. As ambassador for
the 'Women Who Know' campaign, Tisdale calls on women who may be
seeking to prevent pregnancy for a variety of reasons, whether it
be work, education, travel before starting a family or a mom who
isn't quite ready to further expand her family. This campaign acts
as a resource for these women as they seek information about their
options, including Lo Loestrin Fe.
"Women have a lot of options available to them when it comes
to pregnancy prevention, and that comes with a lot of confusion,
which is why it's important to be informed," said
Ashley Tisdale. "I'm
thrilled to be working with Allergan on behalf of Lo
Loestrin® Fe to call
attention to the 'Women Who Know' campaign, and I hope to use my
platform to inspire women across the nation to open up a
conversation with their healthcare providers
— and join me in becoming a 'Woman Who
Knows.'"
Ashley appears in educational video content alongside OB/GYN Dr.
Lakeisha Richardson, in which she
encourages other women to ask questions and engage experts on
subjects related to contraception that they may not know everything
about. This video and more content with Tisdale are now live on
LoLoestrin.com and across Lo Loestrin Fe social media
channels.
"We launched this campaign to encourage and empower women
across the country to seek out the right resources and ask
questions about their options when it comes to contraception,
whether they're looking to start a conversation with their
healthcare provider for the first time, expand their contraceptive
journey into prescription products or just learn a little bit more
about a method they are currently using, like Lo
Loestrin® Fe," said
Erin Capra, Associate VP of
Marketing for Allergan Women's Health. "We joined
forces with Ashley Tisdale, a smart,
talented and successful woman, to create content that supports and
inspires women as they seek out credible resources when it comes to
preventing pregnancy."
Dr. Lakeisha Richardson, a
board-certified Obstetrician and Gynecologist and paid consultant
of Allergan, also plays a role in the content to answer and address
questions from Ashley and show that it's possible to have open,
honest conversations about contraception. As a specialist in
gynecology, she provides insights and answers some of the most
commonly asked questions when it comes to oral contraception,
helping Ashley become a 'Woman Who Knows' and encouraging other
women to educate themselves about their options.
"Having practiced as an OB/GYN in my community for almost 10
years, I work with women every day who have questions when it comes
to pregnancy prevention, so I hope that through this campaign I can
help provide women with the resources to make an informed decision
about their birth control," said Dr. Lakeisha Richardson, F.A.C.O.G.. "I am
honored to have been asked to participate, and I hope that through
the content we are launching today I can help prepare young women
everywhere for a candid discussion with their healthcare provider
about their options, including Lo
Loestrin® Fe."
To see the content created and learn more about one birth
control option, visit LoLoestrin.com.
1 IQVIA™. National Prescription Audit® - TRx/EUTRx
Data: April 2018 - April 2019 (claim derived from the use of
information under license from IQVIA, which expressly reserves all
rights, including rights of copying, distribution, and
republication).
What is Lo Loestrin® Fe?
Lo Loestrin
Fe is a prescription birth control pill used for the prevention of
pregnancy. If you are moderately obese, discuss with your
healthcare provider whether Lo Loestrin Fe is appropriate for
you.
IMPORTANT RISK INFORMATION
WARNING TO WOMEN WHO SMOKE
Do not use Lo Loestrin Fe if you smoke cigarettes and are over 35
years old. Smoking increases your risk of serious cardiovascular
side effects (heart and blood vessel problems) from birth control
pills, including death from heart attack, blood clots, or stroke.
This risk increases with age and the number of cigarettes you
smoke.
Who should not take Lo Loestrin Fe?
Do not use Lo
Loestrin Fe if you have or have had blood clots, history of heart
attack or stroke, high blood pressure that medicine cannot control,
breast cancer or any cancer that is sensitive to female hormones,
liver disease or liver tumors, unexplained bleeding from the
vagina, if you are or may be pregnant, or if you take Hepatitis C
drugs containing ombitasvir/paritaprevir/ritonavir, with or without
dasabuvir, as this may increase levels of liver enzymes in the
blood.
What else should I know about taking Lo Loestrin Fe?
Treatment with Lo Loestrin Fe should be stopped if you have a blood
clot, and at least 4 weeks before and through 2 weeks after major
surgery. You should not take Lo Loestrin Fe any earlier than 4
weeks after having a baby, or if you are breastfeeding. If you
experience yellowing of the skin or eyes due to problems with your
liver, you should stop taking Lo Loestrin Fe. If you are
pre-diabetic or diabetic, your doctor should monitor you while
using Lo Loestrin Fe. Your doctor should evaluate you if you have
any significant change in headaches or irregular menstrual
bleeding.
What are the most serious risks of taking Lo Loestrin
Fe?
Lo Loestrin Fe increases the risk of serious conditions including
blood clots, stroke, and heart attack. These can be
life-threatening or lead to permanent disability.
What are the possible side effects of Lo Loestrin
Fe?
The most common side effects reported by
women taking Lo Loestrin Fe in a study were nausea/vomiting,
headache, spotting or bleeding between menstrual periods, painful
menstruation, weight change, breast tenderness, acne, abdominal
pain, anxiety, and depression.
Birth control pills do not protect you against any sexually
transmitted disease, including HIV, the virus that causes
AIDS.
Please see full Prescribing Information, including Boxed
Warning, for Lo Loestrin Fe:
http://www.allergan.com/assets/pdf/loloestrin_pi.pdf
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website at
www.Allergan.com
© 2019 Allergan. All rights reserved.
Allergan® and its design are trademarks of Allergan,
Inc.
Lo Loestrin® and its design are registered trademarks of
Allergan Pharmaceuticals International Limited.
CONTACTS:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7162
Media:
Lisa Brown
(862) 261-7320
Sara Sanders
(862) 261-8130
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ashley-tisdale-joins-the-allergan-women-who-know-campaign-300892006.html
SOURCE Allergan plc